No­var­tis spin­out resTOR­bio re­verse merges with T cell biotech af­ter big PhI­II fail­ure

The end of their lead pro­gram will, it turns out, spell the end for No­var­tis spin­out resTOR­bio.

Shares for the once well-fund­ed an­ti-ag­ing biotech crum­bled af­ter its lead pro­gram failed a Phase III tri­al last year. The com­pa­ny said they would shift fo­cus to an ear­ly stage Parkin­son’s can­di­date, but that looked like a long shot at the time, and to­day, the com­pa­ny an­nounced they will re­verse merge with Adicet Bio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.